MDM4 and neuroblastoma: A new dual MDM2/MDMX inhibitor ALRN-6924 [305] is under testing (NCT03654716) in a clinical phase 1 trial for neuroblastoma (Table 3), raising new hope for HR-NB treatment using TP53 reactivation.